Janus Kinase Inhibitor
VIDEO: JAK inhibitors have 'transformed' the treatment landscape
VIDEO: Expert discusses excitement for second-generation JAK inhibitors
VIDEO: JAK inhibitors show promise in hematologic malignancies, solid tumors
VIDEO: Triple DMARD therapy, other options for patients who don't respond to JAK inhibitors
VIDEO: Pacritinib ‘can outperform’ ruxolitinib in patients with low platelet counts
Aaron T. Gerds, MD, MS, speaks with Healio about the challenge dosing for ruxolitinib in patients with thrombocytopenia and the development of pacritinib as a Janus kinase inhibitor “specifically for patients with low platelet counts.”
VIDEO: Predicting anemia response to JAK inhibitors among patients with myelofibrosis
Aaron T. Gerds, MD, MS, speaks with Healio about predictive biomarkers of week 24 transfusion independence among patients with myelofibrosis.
FDA approves Xeljanz for active ankylosing spondylitis
The FDA has approved Xeljanz for the treatment of adults with active ankylosing spondylitis who have had an inadequate response, or intolerance to, TNF inhibitors, according to a Pfizer press release.
VIDEO: Expert discusses GLORIA trial results
In this video from ACR Convergence 2021, Kathryn Dao, MD, provided insight on the data from the GLORIA trial, which found that steroids improved disease activity “but at a cost.”
VIDEO: Cardiovascular risk factors associated with JAK inhibitor use in RA
In this video from ACR Convergence 2021, Kathryn Dao, MD, highlighted cardiovascular risk factors to be aware of when prescribing JAK inhibitors for patients with rheumatoid arthritis.